Pharminent

AstraZeneca taps outcomes deals to boost CV, diabetes meds

Two agreements with Harvard Pilgrim for Brilinta and Bydureon will link drug cost to certain patient outcomes — the most recent examples of value-based deals. http://www.biopharmadive.com/news/astrazeneca-harvard-pilgrim-value-outcomes-brilinta-bydureon/443891/

Filed under: Diabetes